IRIDEX (NASDAQ:IRIX) Major Shareholder Shih-Yao David Lin Acquires 22,805 Shares of Company Stock

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin purchased 22,805 shares of IRIDEX stock in a transaction that occurred on Tuesday, March 17th. The stock was acquired at an average price of $1.31 per share, with a total value of $29,874.55. Following the transaction, the insider owned 1,157,363 shares in the company, valued at $1,516,145.53. The trade was a 2.01% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

IRIDEX Price Performance

Shares of NASDAQ:IRIX opened at $0.88 on Thursday. IRIDEX Corporation has a 1-year low of $0.61 and a 1-year high of $1.65. The stock has a market cap of $15.46 million, a P/E ratio of -4.40 and a beta of 0.67. The firm has a fifty day moving average price of $0.73 and a 200 day moving average price of $0.95.

IRIDEX (NASDAQ:IRIX) last posted its quarterly earnings data on Tuesday, August 18th. The medical equipment provider reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06). The business had revenue of $12.57 million for the quarter, compared to the consensus estimate of $13.59 million. Sell-side analysts expect that IRIDEX Corporation will post -0.12 EPS for the current fiscal year.

Key IRIDEX News

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: SEC disclosures show Lin made dozens of purchases totaling substantial share amounts, including transactions of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00. The repeated buying and growing ownership stake may be interpreted as a sign of confidence in IRIDEX’s long-term prospects. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: The filings also include purchases at prices ranging from approximately $0.84 to $1.52, with several individual transactions valued between roughly $20,000 and $58,000. This broad pattern of buying, rather than a single isolated trade, likely attracted speculative interest in the thinly traded stock. IRIDEX major shareholder acquires stock
• Neutral Sentiment: Investors should note that most purchases occurred weeks or months earlier, from March through June and in prior reporting periods; the disclosures are new, but the buying itself is not. The reports therefore provide sentiment support rather than evidence of a new operating development or immediate improvement in revenue and earnings.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down (LULD) pause, indicating that the stock’s rapid move exceeded permitted price bands. This highlights significant volatility and the potential for sharp reversals once trading resumes.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 2nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $3.00.

Hedge Funds Weigh In On IRIDEX

A number of large investors have recently made changes to their positions in IRIX. Weber Capital Management LLC ADV acquired a new stake in IRIDEX in the second quarter valued at $206,616. United Capital Financial Advisors LLC acquired a new position in shares of IRIDEX during the 2nd quarter worth approximately $41,000. Diversify Advisory Services LLC purchased a new stake in IRIDEX in the 2nd quarter valued at approximately $30,000. Diversify Wealth Management LLC acquired a new stake in IRIDEX during the 1st quarter valued at $35,000. Finally, Bank of New York Mellon Corp acquired a new stake in IRIDEX during the 2nd quarter valued at $29,000. Hedge funds and other institutional investors own 20.10% of the company’s stock.

About IRIDEX

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.